The role of CDK4/6 inhibitors in early breast cancer - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34087775/

The use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the treatment of advanced hormone receptor-positive (HR + ) and human epidermal growth factor receptor 2-negative (HER2 - ) breast cancer (BC), leading to a strong interest in thei ...